Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Hardin

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|August 29, 2024
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)Jorge F Maspero, Martti A Antila, Antoine Deschildre, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2024
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with AsthmaIan D Pavord, Lucia De Prado Gómez, Guy Brusselle, et al.
The European Respiratory Journal|September 21, 2023
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE studyAlessandro G Fiocchi, Wanda Phipatanakul, Robert S Zeiger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 1, 2024
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation StudyJorge F Maspero, Anju T Peters, Kenneth R Chapman, et al.
Respiratory Medicine|August 27, 2014
Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGeneJin Hwa Lee, Michael H Cho, Merry-Lynn N McDonald, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.
Allergy|April 14, 2023
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthmaNikolaos G Papadopoulos, Stanley J Szefler, Leonard B Bacharier, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Allergy and Clinical Immunology. in Practice|August 29, 2024
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)Jorge F Maspero, Martti A Antila, Antoine Deschildre, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2024
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with AsthmaIan D Pavord, Lucia De Prado Gómez, Guy Brusselle, et al.
The European Respiratory Journal|September 21, 2023
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE studyAlessandro G Fiocchi, Wanda Phipatanakul, Robert S Zeiger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 1, 2024
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation StudyJorge F Maspero, Anju T Peters, Kenneth R Chapman, et al.
Respiratory Medicine|August 27, 2014
Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGeneJin Hwa Lee, Michael H Cho, Merry-Lynn N McDonald, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.
Allergy|April 14, 2023
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthmaNikolaos G Papadopoulos, Stanley J Szefler, Leonard B Bacharier, et al.
Pageof 5